Close Menu

NEW YORK (GenomeWeb) – The College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and the American Society of Clinical Oncology (ASCO) have issued new guidelines for clinicians using HER2 amplification or mutation testing to inform treatment of advanced gastroesophageal adenocarcinoma, a form of cancer that originates near the junction of the esophagus and stomach.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.